NASDAQ:ARQL

ArQule (ARQL) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$20.00
$20.00
50-Day Range
$20.00
$20.00
52-Week Range
$3.15
$20.45
Volume
N/A
Average Volume
5.27 million shs
Market Capitalization
$2.42 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ARQL stock logo

About ArQule Stock (NASDAQ:ARQL)

ArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. The company's pipeline includes ARQ 531, an orally bioavailable, potent and reversible dual inhibitor of wild type and C481S-mutant Bruton's tyrosine kinase that is in Phase I trial for patients with B-cell malignancies refractory to other therapeutic options; and miransertib (ARQ 092), a potent and selective inhibitor of the protein kinase B (AKT), a serine/threonine kinase, which is in Phase Ib in combination with the hormonal therapy and anastrozole in patients with advanced endometrial cancer. Its pipeline also comprises ARQ 75, a potent and selective inhibitor of AKT that is in Phase I clinical development for solid tumors harboring AKT, phosphoinositide 3-kinase or phosphatase, and tensin homolog loss mutations. In addition, the company's pipeline includes Derazantinib (ARQ 087), a multi-kinase inhibitor designed to preferentially inhibit the fibroblast growth factor receptor (FGFR) family of kinases that is in a registrational clinical trial in intrahepatic cholangiocarcinoma in patients with FGFR2 fusions. ArQule, Inc. has license agreements with Basilea Pharmaceutica Limited and Roivant Sciences Ltd. The company was founded in 1993 and is headquartered in Burlington, Massachusetts.

ARQL Stock News Headlines

Merck Sharp & Dohme Corp.'s Net Worth
ASCO Live Blog: Saturday
See More Headlines
Receive ARQL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ArQule and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/30/2019
Today
5/18/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ARQL
CUSIP
04269E10
Fax
N/A
Employees
36
Year Founded
N/A

Profitability

Net Income
$-15,480,000.00
Net Margins
-805.61%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$25.76 million
Book Value
$0.72 per share

Miscellaneous

Free Float
N/A
Market Cap
$2.42 billion
Optionable
Optionable
Beta
2.49
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. Paolo Pucci (Age 58)
    CEO & Director
  • Mr. Peter S. Lawrence J.D. (Age 56)
    Pres, COO, Gen. Counsel & Sec.
  • Dr. Brian Schwartz (Age 57)
    Chief Medical Officer & Sr. VP
  • Mr. Robert J. Weiskopf (Age 68)
    CFO, Sr. VP, Principal Accounting Officer & Treasurer
  • Dr. Marc Schegerin M.D.
    CFO, Head of Strategy & Treasurer

ARQL Stock Analysis - Frequently Asked Questions

How were ArQule's earnings last quarter?

ArQule, Inc. (NASDAQ:ARQL) announced its quarterly earnings results on Wednesday, October, 30th. The biotechnology company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.08) by $0.01. The biotechnology company earned $0.21 million during the quarter, compared to the consensus estimate of $1.20 million. ArQule had a negative net margin of 805.61% and a negative trailing twelve-month return on equity of 33.10%. During the same period in the previous year, the business earned ($0.05) earnings per share.

What other stocks do shareholders of ArQule own?
This page (NASDAQ:ARQL) was last updated on 5/18/2024 by MarketBeat.com Staff

From Our Partners